T-Therapeutics raises $133 million; J&J, Lilly back TCR cancer drugs

T-Therapeutics, a biotechnology start-up based in Cambridge, UK, announced on Thursday, 5 November 2026 that it has raised $133 million in an oversubscribed Series B round to take its first two experimental medicines into clinical trials. The round was co-led by Advent Life Sciences and the British Business Bank, and new investors included the venture arms of Johnson & Johnson and Eli Lilly. The company is developing a type of drug called a TCR bispecific, or T-cell engager, for cancer and autoimmune diseases.

The round is a sign of where investors see the next opportunity in medicine. T-Therapeutics works on T-cell receptors (TCRs), the molecules that immune cells use to recognise targets inside other cells. A TCR bispecific, or T-cell engager, is a single drug designed to grab a diseased cell with one end and an immune T-cell with the other, bringing them together so the immune system can act. Companies in this field say TCRs can recognise targets that many antibody drugs cannot reach, and hope to treat cancers and autoimmune conditions that lack good options. These are aims, not results: the company's drugs have yet to be tested in patients.

The list of investors matters as much as the amount. Large drug makers such as Johnson & Johnson and Eli Lilly invest through their venture arms, which gives them early sight of new science. The British Business Bank, which co-led the round, is owned by the UK government. Tencent's continued investment shows the round's international reach.

For investors and founders, the deal shows investors putting large sums into a company just before its first clinical trials. For India, which has a growing base of biotech start-ups and contract research companies, it is a reminder of the kind of investor syndicates and specialist funds that back such ventures abroad. This story describes a funding event and is not investment advice.

Peepals calculation: The $133 million Series B is about 1.5 times the company's entire $91 million Series A (133 ÷ 91 ≈ 1.46). Together, the two rounds bring T-Therapeutics' disclosed funding to about $224 million (91 + 133 = 224), of which the new round is about 59% (133 ÷ 224 ≈ 0.59). Our calculation from the reported figures.

Short-term: T-Therapeutics will use the money to start clinical trials of its two lead programmes. The new Chief Development Officer will oversee that move into human studies.

Long-term: If the trials produce positive proof-of-concept data, the company could attract larger partnerships or further funding; if not, it will face the setbacks common in drug development. Either way, results will take time.

Who is affected: Patients with hard-to-treat cancers and autoimmune diseases in the long run, T-Therapeutics' staff and investors, and the UK life-science sector.

Questions and Answers